Department of Psychiatry, Faculty of Medicine and Health, Northern Clinical School, The University of Sydney, Sydney, NSW, Australia.
Academic Department of Psychiatry, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW, 2065, Australia.
CNS Drugs. 2021 Jun;35(6):619-641. doi: 10.1007/s40263-021-00823-y. Epub 2021 May 21.
Feeling irritable is a common experience, both in health and disease. In the context of psychiatric illnesses, it is a transdiagnostic phenomenon that features across all ages, and often causes significant distress and impairment. In mood disorders, irritability is near ubiquitous and plays a central role in diagnosis and yet, despite its prevalence, it remains poorly understood. A neurobiological model of irritability posits that, in children and adolescents, it is consequent upon deficits in reward and threat processing, involving regions such as the amygdala and frontal cortices. In comparison, in adults with mood disorders, the few studies that have been conducted implicate the amygdala, orbitofrontal cortices, and hypothalamus; however, the patterns of activity in these areas are at variance with the findings in youth. These age-related differences seem to extend to the neurochemistry of irritability, with links between increased monoamine transmission and irritability evident in adults, but aberrant levels of, and responses to, dopamine in youth. Presently, there are no specific treatments that have significant efficacy in reducing irritability in mood disorders. However, treatments that hold some potential and warrant further exploration include agents that act on serotonergic and dopaminergic systems, especially as irritability may serve as a prognostic indicator for overall clinical responsiveness to specific medications. Therefore, for understanding and treatment of irritability to advance meaningfully, it is imperative that an accurate definition and means of measuring irritability are developed. To achieve this, it is necessary that the subjective experience of irritability, both in health and illness, is better understood. These insights will inform an accurate, comprehensive, and valid interrogation of the qualities of irritability in health and illness, and allow not only a clinical appreciation of the phenomenon, but also a deeper understanding of its important role within the development and manifestation of mood disorders.
感到烦躁是一种常见的体验,无论是在健康还是疾病状态下。在精神疾病的背景下,它是一种跨诊断现象,跨越所有年龄段,常常导致显著的痛苦和障碍。在心境障碍中,烦躁几乎无处不在,在诊断中起着核心作用,但尽管它很普遍,却仍未被充分理解。烦躁的神经生物学模型假设,在儿童和青少年中,它是由于奖励和威胁处理缺陷引起的,涉及杏仁核和前额皮质等区域。相比之下,在患有心境障碍的成年人中,为数不多的研究表明涉及杏仁核、眶额皮质和下丘脑;然而,这些区域的活动模式与年轻人的研究结果不一致。这些与年龄相关的差异似乎延伸到烦躁的神经化学,在成年人中,增加单胺传递与烦躁之间存在关联,但在年轻人中,多巴胺的水平和反应异常。目前,没有特定的治疗方法对减少心境障碍中的烦躁有显著疗效。然而,一些有潜力并值得进一步探索的治疗方法包括作用于 5-羟色胺能和多巴胺能系统的药物,特别是因为烦躁可能是对特定药物整体临床反应性的预后指标。因此,为了使对烦躁的理解和治疗有意义地进展,必须制定出准确的定义和测量烦躁的方法。为了实现这一点,有必要更好地理解健康和疾病中烦躁的主观体验。这些见解将为健康和疾病中烦躁的性质进行准确、全面和有效的探究提供信息,不仅可以从临床角度了解这一现象,还可以更深入地理解其在心境障碍的发展和表现中的重要作用。